OrthoPediatrics - KIDS Stock Forecast, Price & News

5 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for OrthoPediatrics in the last year. There are currently 5 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" KIDS shares.
View KIDS analyst ratings or view top-rated stocks.

5 brokers have issued 12 month price objectives for OrthoPediatrics' shares. Their KIDS share price forecasts range from $50.00 to $62.00. On average, they predict the company's stock price to reach $55.17 in the next year. This suggests a possible upside of 24.6% from the stock's current price.
View analysts price targets for KIDS or view top-rated stocks among Wall Street analysts.

OrthoPediatrics' stock was trading at $39.73 at the beginning of the year. Since then, KIDS shares have increased by 11.5% and is now trading at $44.29.
View the best growth stocks for 2023 here.

The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 3rd 2023.
View our KIDS earnings forecast.

OrthoPediatrics Corp. (NASDAQ:KIDS) released its quarterly earnings results on Tuesday, February, 28th. The company reported ($0.32) EPS for the quarter, missing the consensus estimate of ($0.22) by $0.10. The company earned $30.99 million during the quarter, compared to analysts' expectations of $31.01 million. OrthoPediatrics had a negative trailing twelve-month return on equity of 5.76% and a net margin of 1.03%.

ETFs with the largest weight of OrthoPediatrics (NASDAQ:KIDS) stock in their portfolio include SPDR S&P Health Care Equipment ETF (XHE), First Trust NASDAQ BuyWrite Income ETF (FTQI), Principal Healthcare Innovators ETF (BTEC) and iShares Micro-Cap ETF (IWC) and

OrthoPediatrics updated its FY 2023 earnings guidance on Tuesday, February, 28th. The company provided EPS guidance of for the period. The company issued revenue guidance of $146.00 million-$149.00 million, compared to the consensus revenue estimate of $149.57 million.

15 employees have rated OrthoPediatrics Chief Executive Officer Mark Throdahl on Glassdoor.com. Mark Throdahl has an approval rating of 100% among the company's employees. This puts Mark Throdahl in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

Based on aggregate information from My MarketBeat watchlists, some companies that other OrthoPediatrics investors own include AbbVie (ABBV), Freeport-McMoRan (FCX), Gilead Sciences (GILD), Intel (INTC), Advanced Micro Devices (AMD), CRISPR Therapeutics (CRSP), Cisco Systems (CSCO), Walt Disney (DIS), Enterprise Products Partners (EPD) and NVIDIA (NVDA).

(KIDS) raised $52 million in an initial public offering on Thursday, October 12th 2017. The company issued 4,000,000 shares at $12.00-$14.00 per share. Piper and Jaffray Stifel served as the underwriters for the IPO and William Blair and BTIG were co-managers.

OrthoPediatrics trades on the NASDAQ under the ticker symbol "KIDS."

Shares of KIDS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of KIDS stock can currently be purchased for approximately $44.29.

OrthoPediatrics (NASDAQ:KIDS) has a market capitalization of $1.02 billion and generates $122.29 million in revenue each year. The company earns $1.26 million in net income (profit) each year or $0.03 on an earnings per share basis.

The company employs 133 workers across the globe.

OrthoPediatrics' mailing address is 2850 Frontier Drive, Warsaw IN, 46582. The official website for the company is www.orthopediatrics.com. The company can be reached via phone at (574) 268-6379, via email at tbui@theruthgroup.com, or via fax at 574-269-3692.